This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Indolent Lymphoma Overview
- Therapeutics Development
- Pipeline Products for Indolent Lymphoma - Overview
- Pipeline Products for Indolent Lymphoma - Comparative Analysis
- Indolent Lymphoma - Therapeutics under Development by Companies
- Indolent Lymphoma - Therapeutics under Investigation by Universities/Institutes
- Indolent Lymphoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Indolent Lymphoma - Products under Development by Companies
- Indolent Lymphoma - Products under Investigation by Universities/Institutes
- Indolent Lymphoma - Companies Involved in Therapeutics Development
- AbbVie Inc.
- Affimed Therapeutics AG
- Altor BioScience Corporation
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Biothera, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Incyte Corporation
- Infinity Pharmaceuticals, Inc.
- Juno Therapeutics Inc.
- Kite Pharma, Inc.
- MedImmune, LLC
- Merck & Co., Inc.
- Merck KGaA
- Millennium Pharmaceuticals, Inc.
- MorphoSys AG
- Trillium Therapeutics Inc.
For more information visit http://www.researchandmarkets.com/research/qmrgwx/indolent_lymphoma